REFERENCES
- Begsjö P, Jenssen H, Vellar OD. Dysmenorrhea in industrial workers. Acta Obstet Gynecol Scand 1975;54:255–9
- Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982;144:655–60
- Äkerlund M. The pathophysiology of dysmenorrhea. In Cameron IT, Fraser IS, Smith SK, eds. Clinical Disorders of the Endometrium and the Menstrual Cycle. Oxford, UK: Oxford University Press, 1998:281–8
- Lumsden MA. The clinical treatment of dysmenorrhea. In Cameron IT, Fraser IS, Smith SK, eds. Clinical Dis- orders of the Endometrium and the Menstrual Cycle. Oxford, UK: Oxford University Press, 1998:289–96
- Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive device: a multicenter study. International Committee for Contraceptive Research (ICOR). Fertil Steril 1994;61:70–7
- Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485–8
- Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996;15:430–40
- Sivin I. The Copper T 380 Intrauterine Device. A Summary of Scientific Data. New York: The Population Council, 1992
- Sivin I, El-Mahgoub S, McCarthy T. Long-term con- traception with the levonorgestrel 20 mcg/day (LNg20) and the copper T380Ag intrauterine devices: a five-year randomised study. Contraception 1990;42:361–78
- Wildemeersch D, Schacht E. Endometrial suppression with a new ‘frameless’ levonorgestrel-releasing intra- uterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas 2000;36:63–8
- Wildemeersch D, Schacht E. Contraception with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2000;5:234–40
- Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001;6:93–101
- Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhea: the importance of both prostaglandins E2 and F2a. Br J Obstet Gynaecol 1983;90:1135–40
- Strömberg P, Äkerlund M, Forsling ML, Kindahl H. Involvement of prostaglandins in vasopressin stimula- tion of the human uterus. Br J Obstet Gynaecol 1983;93:332–7
- Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Am J Obstet Gynecol 1984;148:96–103
- Buttram VC, Reiter RC. Uterine leiomyomas: etio- logy, symptomatology and management. Fertil Steril 1981;36:433–45
- Donnez J, Schindler AE, Wallweiner D, Audebert A. Fibroids: management and treatment. In Lunenfeld B, Insler V, eds. GnRH Analogues: The State of the Art 1996. Carnforth, UK: Parthenon Publishing, 1996:71–82
- Janssen CA, Scholten PC, Heintz APM. Menorrhagia – a search for epidemiological risk markers. Maturitas 1997;28:19–25
- Rybo G. Population studies of menorrhagia. Res Clin Forums 1983;5:77–81
- Cameron IT, Smith SK. Menorrhagia. In Greer I, Turpie A, Forbes C, eds. Haemostasis and Thrombosis in Obstetrics and Gynecology. London, UK: Associated Books, 1992:77–93